Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2029

Conditions
Smoldering Multiple Myeloma
Interventions
OTHER

Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.

"Patients with high-risk smoldering myeloma will be prospectively followed and chart review will be performed to determine if progression events happen, and how they happen.~All patients on the study are recommended to undergo the following standard of care surveillance protocol:~* Complete Blood Count (CBC), Complete Metabolic Panel (CMP), myeloma blood tests (serum kappa/lambda light chains, monoclonal protein evaluation, immunoglobulin levels), to be done monthly for first year, and then every two months for the second year.~* WB DW-MRIs every 6 months during the study period.~* 24-hour urine Immunofixation/electrophoresis is expected to be completed approximately every 6 months.~* Bone marrow biopsy will be performed annually during the study time-period."

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute at the University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER